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Abstract
Sarcopenia and frailty are common in older persons and pose particular challenges for 
health and social care systems especially in the context of global population ageing. 
Sarcopenia, the loss of skeletal muscle mass, strength and function with age is associated 
with adverse individual physical and metabolic changes contributing to morbidity and 
mortality. The health and socioeconomic implications of sarcopenia are also consider-
able. Sarcopenia is a core component of physical frailty that together impact negatively 
on an individual’s capability to live independently. Frailty is a biological syndrome of 
low reserve and resistance to stressors resulting from cumulative declines across multi-
ple physiological systems that collectively predispose an individual to adverse outcomes. 
Frailty develops along a continuum from independence through to death as physiological 
reserves progressively diminish an individual’s capacity to recover from an acute insult 
or illness. Managing sarcopenia and frailty involves the multidisciplinary led comple-
tion of a comprehensive care plan that is patient centred, responsive to the needs of the 
patient and adaptable therefore enabling an individual to maintain their independence.
Keywords: Sarcopenia, frail, epidemiology, Comprehensive Geriatric Assessment
1. Introduction
Over the past two centuries, there has been a demographic transformation across the world 
and people are living longer [1]. For the first time in history, people can expect to live beyond 
their 60th birthday. In fact, survival to age 80 is anticipated to be the norm for all of today’s 
young people. People aged 60 or over are set to increase from 841 million to more than 2 bil-
lion between 2013 and 2050. This equates to 21.1% of the world’s population [1]. Globally, 
the number of people aged 80 years or over, the “oldest-old”, is growing even faster. In 2000, 
there were 71 million people aged 80 or over worldwide. Since then, the number of oldest-old 
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has grown by 77% to 125 million in 2015, and it is projected to increase by 61% over the next 15 
years, reaching nearly 202 million in 2030. Projections indicate that in 2050 the oldest-old will 
number 434 million globally, having more than tripled in number since 2015 [2]. These demo-
graphic changes are largely due to the advances in public health and modern medicine that 
have reduced early life mortality, reduced the rate of infectious diseases [3] and have allowed 
people to live with one or more long-term conditions. Whilst this is a cause for celebration, 
these cumulative changes pose significant challenges for delivering health and social care to 
older people in all nations concerned.
The situation within the UK is no different. Medical and technological advances in the treatment 
of illnesses and diseases have improved mortality rates in the oldest age groups. In 2013–2015, 
a UK male aged 85 could expect to live to age 90.8 years and a female to 91.8 years. Life expec-
tancy at birth has increased throughout England, Scotland, Wales and Northern Ireland due to 
improvements in mortality in older age. Life expectancy is highest in England with Scotland hav-
ing the lowest of the four UK constituent countries (Office of National Statistics 2016, ONS.gov.uk).
However, numerous people who are living longer in the UK do so with one or more long-term 
medical conditions and many are living with frailty. The clinical conditions of sarcopenia 
and frailty are particularly complex expressions of ageing that impact a range of health and 
social care settings [4, 5]. Sarcopenia is associated with adverse individual physical and meta-
bolic changes contributing to morbidity and mortality, whilst frailty is defined as a state of 
increased vulnerability as a consequence of cumulative physiological decline across multiple 
systems predisposing to poor resolution of homeostasis after a stressor event, which increases 
the risk of adverse outcomes [4, 6]. In this chapter, we will review the epidemiology, patho-
genesis, diagnosis of sarcopenia and frailty as well as give an overview of Comprehensive 
Geriatric Assessment (CGA) as a method of systematically evaluating an older person’s treat-
ment, management and long-term follow-up needs.
2. Skeletal muscle and sarcopenia
Skeletal muscle comprises approximately 40% of total body mass and therefore constitutes one of 
the largest organ systems of the body [7]. Skeletal muscle plays an essential role in both physical, 
for example, locomotion and metabolic functioning, for example, thermoregulation, metabolism 
of glucose and amino acids. Muscle is also a reservoir for proteins and energy that can be utilised in 
periods of stress or undernutrition, for example, acute deterioration in health and hospitalisation.
2.1. Diagnosing sarcopenia
Sarcopenia has previously been defined based solely on lean mass as a function of height 
(appendicular lean mass [ALM] is measured by dual-energy X-ray absorptiometry [DXA] 
divided by height squared) where sarcopenia was diagnosed −1 to −2 SD below gender-spe-
cific mean values of a younger control group [8]. However, direct proportionality between loss 
of muscle mass and impaired strength/function cannot be inferred as longitudinal as well as 
cross-sectional studies show that younger individuals can be stronger and older individuals 
are weaker than would be predicted by their muscle mass [9, 10]. Therefore muscle quality 
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or force generated per unit area is important and the definition of sarcopenia now extends to 
encompass loss of strength and or physical performance [6, 10]. Sarcopenia, is the progressive 
and generalised loss of skeletal muscle mass, strength and physical performance with age and 
as such it is a core component of physical frailty [6, 11, 12]. Sarcopenia is associated with a 
broad array of adverse physical and metabolic outcomes including falls [13], disability, hospi-
talisation, diabetes [14], osteoporosis [15] and also mortality [16]. The economic costs associ-
ated with ‘sarcopenia’ in the year 2000 were estimated to be $18.5 billion in the USA alone [17].
Recent diagnostic algorithms include those proposed by EWGSOP [6], The International 
working group (IWG) on sarcopenia [18], The Foundation for the National Health Institutes of 
Health (FNIH) Sarcopenia Project [11] and the Asian Working Group for Sarcopenia (AWGS) 
[19]; the later driven by the need to account for ethnic variations in body composition and 
muscle function in order to further research sarcopenia in the Asian subcontinent.
The EWGSOP definition requires the presence of slower walk speed (<0.8 m/s) [20] or weaker 
strength (grip <30 kg for men, <20 kg for women) [21] in combination with low muscle mass 
(defined as ALM/ht2 ≤7.23 kg/m2 for men and ≤5.67 kg/m2 for women). The International 
Working Group (IWG) on sarcopenia included impaired physical performance in addition to 
slow walk speed before measuring muscle mass in their working definition for the diagnosis 
of sarcopenia. The Foundations of National Institutes of Health (FNIH) sarcopenia project 
based in the USA incorporated clinically relevant cut points of low muscle mass and strength 
(grip strength <26 kg for men and <16 kg for women and ALM adjusted for BMI <0.789 for 
men and <0.512 for women) [11]. Similarly, the AWGS included gait speed <0.8 mm/s, ALM/
ht2 <7.0 m2 in men and <5.4 kg/m2 in women and grip strength <26 kg for men and <18 kg in 
women [19] in their working definition of sarcopenia. From a clinical point of view, these 
algorithms enable case finding for sarcopenia and conceptually identify stages of sarcopenia 
that allow intervention. For example, the pre-sarcopenia stage is characteristic of low mus-
cle mass without impact on muscle strength or physical performance, the sarcopenia stage 
is characterised by low muscle mass, low muscle strength or poorer physical performance, 
whilst severe sarcopenia is when all three criteria within the algorithm are met [6].
2.2. Prevalence of sarcopenia
The prevalence of sarcopenia increases with age but figures are influenced by the diagnostic 
algorithm used, ethnic population studied, cut-off values for lean mass and function and the 
health care setting, that is, community versus in hospital [22]. For example, a recent system-
atic review reported that the prevalence rates differed for community-dwelling older people 
aged ≥60 years (up to 29%), in long-term care age >70 years (up to 33%) and in an acute care 
hospitals, age ≥ 65 years (up to 10%) [23].
2.3. Measuring muscle mass
The commonest approach to measuring muscle mass is through bioimpedance analysis (BIA) 
and where available, dual-energy X-ray absorptiometry (DXA) scanning. Computerised 
tomography (CT) and magnetic resonance imaging (MRI) can also be used [24]. The approach 
that is undertaken to measure muscle mass is dependent on feasibility, access, costs and sample 
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size. For example, BIA utilises portable equipment and can be used across a range of health 
care settings and calculates fat-free mass rather than true muscle mass based on the electri-
cal conductivity of various body tissues. Whole body DXA will enable the calculation of total 
and appendicular lean mass but may overestimate lean mass values in those with extracellular 
fluid accumulation. Computerised tomography (CT) and magnetic resonance imaging (MRI) 
can differentiate fat from muscle, which can be useful to make assumptions on muscle quality. 
However, high operational costs and radiation, in the case for CT, limits their use in the diag-
nosis of sarcopenia.
2.4. Measuring muscle strength
Grip strength measured using hand-held dynamometry, has gained wide acceptance as a reli-
able and valid measure of muscle strength across health care settings and is an integral compo-
nent in the international diagnostic algorithms for sarcopenia [25–27]. Other methods to measure 
muscle ‘strength’ include ascertainment of knee extensor power, isometric knee strength and 
quadriceps torque but these require static and bulky equipment that are not readily portable 
and can be impractical in routine clinical practice as well as in epidemiological studies.
2.5. Measuring physical performance
Slower gait speed is associated with risk of future morbidity and mortality and is therefore 
suitable for inclusion in diagnostic algorithms for sarcopenia [28]. Other objectively measured 
physical performance measures such as chair rise time; time taken to complete five sit to stand 
actions and standing balance; and the time for sustaining balance on one leg have also been 
associated with higher risk of all-cause mortality in older people [16, 29]. Gait speed requires 
intact coordination, neural and joint control so may not be practical in context of acutely 
unwell hospitalised older people. Grip strength measurements in this situation may have bet-
ter predictive value and be more feasible [25–27, 30].
2.6. Questionnaires to aid the diagnosis of sarcopenia
The SARC-F questionnaire was developed to predict poor muscle function [31, 32] and is 
based on five questions that ascertain how much difficulty an individual has performing the 
following parameters: ability to rise from a chair, walk assisted or unassisted, climb stairs, 
carry heavy loads (as a measure of strength) and ascertainment on the number of falls a per-
son has had in the last year.
Each parameter is assigned a score: 0 (none); 1(some) or 2 (a lot); the falls parameter (none = 0, 
1–3 = 1, 4 or more = 2). A total score of ≥4 (scale 0–10) suggests that the subject is symptomatic 
of sarcopenia. The SARC-F questionnaire has been shown to have excellent specificity but 
poor sensitivity for sarcopenia based on the consensus criteria from the IWG, EWGSOP and 
AWG. However, it has been shown to predict physical limitation over a four-year follow-up 
and may be useful for case identification and subsequent diagnostic evaluation for sarcopenia 
in community based but not hospital or care home-based settings [33].
Despite the recent progress in refining and implementing diagnostic criteria for sarcope-
nia over the past decade, there is no consensus on global diagnostic criteria for sarcopenia 
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based on cut-off values for skeletal muscle mass indices, grip strength and walking speed. 
In fact, the variance in the criteria indicate that ethnic, gender and cultural differences dic-
tate population-specific criteria are required in order to account for the genome/environment 
interactions that contribute to sarcopenia, thus influencing the design of both observational 
and intervention studies [24, 34].
2.7. Pathogenesis of sarcopenia
In sarcopenic muscle, the rate of muscle injury (from normal contraction) exceeds that of 
repair and regeneration. There may also be decreased satellite cell (muscle stem cell), pro-
liferative capability and renewal [35, 36] in combination with altered inter- and intracellu-
lar environments that favour catabolism. This increase in catabolism is associated with a 
decrease in growth factors such as circulating insulin, growth hormone and testosterone and 
muscle-specific IGF-1 levels [37]. Furthermore, the production of reactive oxygen species 
and oxidative stress can lead to mitochondrial DNA damage and a progressive decline in 
mitochondrial function and energy depletion [38]. At a tissue level, skeletal muscle is con-
tinuously remodelled in response to workload, tension, nutrition and anabolic stimulation. 
The cues associated with the age-related decline in muscle mass and strength include behav-
ioural (i.e. decrease in physical activity/sedentary lifestyle), extrinsic (i.e. undernutrition) and 
intrinsic factors (i.e. hormonal changes, inflammation, oxidative stress and denervation) [39] 
(Figure 1).
Figure 1. The main mechanisms involved in the aetiology of sarcopenia.
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The complex dynamic genome/environment interplay involved in the balancing of muscle 
synthesis and breakdown is mediated through multiple cell signalling pathways [40] that 
include IGF-1/AKT/mTOR and NF-κB (nuclear factor-kB). These pathways influence the bal-
ance between synthesis and degradation. For example, the IGF-I/AKT/mTOR pathways pro-
mote protein synthesis and the maintenance of skeletal muscle mass. By contrast, the activation 
of NF-kB by inflammatory mediators including tumour necrosis factor (TNF) and interleukin 
6 (IL-6) upregulate the E3 ubiquitin ligases MAFbx (atrogin-1) and MURF-1, which signal the 
muscle atrophic process. Skeletal muscle ageing is also characterised by a continuous cycle of 
denervation and reinnervation as a consequence of the loss of alpha-motor neurones within 
the central nervous system (CNS), withdrawal of nerve terminals from the neuromuscular 
junctions (NMJ) and axonal sprouting from neighbouring neurons collectively giving rise to 
larger, inefficient motor units.
Remodelling of skeletal muscle tissue through neuropathic, neurohormonal and inflamma-
tory pathways leads to a reduction in muscle cross-sectional area, volume and a reduced 
rate of force generation. This is characterised by the presence of fewer type I oxidative (slow 
twitch) and type II glycolytic (fast twitch) myofibres as well as myofibre atrophy. The loss of 
type II fibres, with concomitant decrease in satellite cells [41], is associated with decreased 
strength and ability to generate power. Moreover, there is a concurrent increase in non-con-
tractile material within the fascicles that affects muscle quality. Collectively, these processes 
lead to the reduced muscle functional performance.
2.8. A life course approach to understand the aetiology of sarcopenia
Muscle development in humans begins at 6 weeks of gestation and continues until approxi-
mately 24 weeks when the total number of fibres is set. Any subsequent increase in muscle 
bulk occurs by hypertrophy as evidenced by an increase in fibre cross-sectional area, and 
not by hyperplasia. Therefore, the number of muscle fibres formed prenatally influences the 
potential for postnatal hypertrophy [42]. Muscle mass increases during childhood and adoles-
cence until adult muscle cross-sectional areas are reached shortly after puberty. Muscle mass 
then remains relatively constant in early adulthood until the later part of the 4th decade of life 
when a decline begins [43].
Skeletal muscle strength is determined, in part, by muscle mass, which is a function of myo-
fibre size and number. On average, men have greater muscle mass and strength than women 
at any given point in the life course [44]. Between the ages of 20 and 80 years, total lean body 
mass has been reported to decline by approximately 18% in males and by 27% in females 
[45]. Therefore, the ‘health’ of skeletal muscle in an older person is a function of the peak 
levels attained in early life and the extrinsic and intrinsic changes operating through middle 
years into old age, for example, physical activity, nutrition, disease and disuse and hormonal 
changes. There is also robust epidemiological evidence suggesting that low birth weight, a 
marker of an adverse early intrauterine environment, is associated with a poorer grip strength 
in older adults and that the mechanism may be driven by myofibre development and number 
[46, 47].
Frailty and Sarcopenia - Onset, Development and Clinical Challenges6
3. Frailty
Frailty is a common clinical syndrome, which is often seen in older adults, especially in women 
compared to men and younger aged adults [48–50]. Frailty is distinct from disability and comor-
bidity and independently carries a high risk for poor health outcomes such as falls, hospitalisa-
tion, disability and mortality [51, 52]. Whilst, sarcopenia contributes to and is a core component of 
physical frailty, the syndrome of frailty is comprised of several interlinked domains that impact 
on an older person’s independence, quality of life and medium- to long-term outcomes. Cognitive 
frailty refers to progressive cognitive decline in absence of a diagnosis of dementia, social frailty 
refers to loneliness and the lack of robust social networks as well as poor income whilst psycho-
logical frailty refers to the inherent traits in an individual that may predispose an individual to 
adversity, for example, bereavement, low mood, lack of motivation and labile emotions [53, 54]. 
Multimorbidity, defined by the UK National Institute for Health and Care Excellence (NICE, 
guidance 56), is the presence of two or more distinct long-term conditions, is also associated with 
a higher risk of developing frailty [54, 55]. This conceptual model illustrates that assessing and 
managing a patient who is living with frailty requires a more holistic approach to manage the 
cause, or combination of causes that have precipitated acute decompensation [5] (Figure 2).
Frailty is best understood as a multisystem disorder, with perhaps both independent and 
linked mechanisms operating across organ or physiological systems. Accumulating dysregu-
lation across multiple systems can negatively affect previous normal functional homeostatic 
mechanisms accelerating the development and progression of frailty. This is relevant not only 
for improved understanding of this syndrome but also because a key implication of loss of 
reserve across multiple systems is that therapeutic intervention of any single system, that 
is, endocrine, brain, immune/inflammatory or indeed an individual domain, that is, social, 
physical or cognitive, is unlikely to ameliorate the abnormal health state of frailty. For those 
living with frailty, even a minor insult such as a minor infection or change in medication can 
lead to a large disproportionate change in an individual’s health and social care state that 
inevitably results in an acute hospital admission (Figure 2).
Older people living with frailty do so as a consequence of accelerated loss of biological 
reserves across multiple systems over a lifetime and individuals experience frequent transi-
tions between frailty states over time. Using the life course approach to conceptualise frailty 
is worth considering as this broadens the window of opportunity to identify markers and 
mechanisms contributing to frailty with a view to intervention [56] (Figure 2). For example, 
the presence of weight loss or weakness earlier in the life course, that is, slow walk speed and 
exhaustion may identify people at especially high risk of rapid decline [57].
3.1. Identification of frailty
Detection of frailty should be an essential part of assessment of older people and the iden-
tification of reliable tools to determine frailty within acute and community settings is cur-
rently a research and clinical priority. Recognising and identifying people who are living 
with frailty not only enables clinicians and health care professionals to respond quickly and 
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appropriately to minimise exposures that may not be beneficial or could be harmful, that is, 
polypharmacy, invasive investigations, but also anticipate and prevent functional decline and 
potentially reverse the state of frailty with appropriate interventions.
The two established international models of frailty are the phenotype model and the cumula-
tive deficit model. The phenotype model developed by Fried identifies frailty by the presence 
of at least three of five physical characteristics: weight loss, exhaustion, low energy expen-
diture, slow walking speed and low handgrip strength [51]. The cumulative deficit model 
developed by Rockwood et al. identifies frailty on the basis of the accumulation of a range 
of ‘deficits’, which can be symptoms, sensory deficits, clinical signs, diseases, disabilities and 
abnormal laboratory test results that then allow an index to be calculated. The frailty index is 
a function of the number of deficits present in an individual divided by the total number of 
deficits possible within the population sample [58]. The number of deficits measures accumu-
lated vulnerability, which is related to adverse outcomes. In this regard, a frailty index will 
range from 0 to 1, with values over 0.67 identifying a level of frailty beyond which accumula-
tion of further deficits is not sustainable with life [59]. Despite the difference in approaches 
to measuring frailty, both tools are able to predict adverse outcome, which provides support 
for the notion of frailty as a unified construct [60]. In clinical practice, identification of frailty 
using the Clinical Frailty Scale (CFS), a visual tool based on a comprehensive clinical assess-
ment of a patient, enables assignment of a frailty category [58]. There are seven CFS categories 
Figure 2. Healthy ageing is depicted by the blue solid line. Frailty (red line) develops as a continuum from being 
physiologically robust and independent to being at high risk of hospitalisation, institutionalisation and death. In more 
physiologically robust individuals, full recovery is likely after an insult, for example, infection (A), but later in the time 
course, moderate to severe frailty predisposes to recurrent hospital admissions as a consequence of a disproportionate 
deterioration in health and social and/or psychological health from a relatively minor insult or stress (B). The recovery 
from subsequent insults takes longer as physiological reserves are depleted until the individual cannot compensate 
adequately, and the ability to perform daily activities diminishes leading to dependency and disability.
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ranging from 1 (fit) to 7 (severe frailty) and increasing CFS frailty has been demonstrated to 
have predictive validity for adverse outcomes of institutionalisation and mortality. In outpa-
tient settings, The PRISMA-7 questionnaire, can be used to identify persons who are living 
with frailty and disability. These questions are:
1. Are you more than 85 years? Yes = 1 point
2. Male? Yes = 1 point
3. In general, do you have any health problems that require you to limit your activities? 
Yes = 1 point
4. Do you need someone to help you on a regular basis? Yes = 1 point
5. In general, do you have any health problems that require you to stay at home? Yes = 1 point
6. In case of need, can you count on someone close to you? No = 1 point
7. Do you regularly use a stick, walker or wheelchair to get about? Yes = 1 point
A score of > 3 can be used to identify frailty.
A further important concept of frailty as a syndrome is that individuals may have previ-
ously unrecognised and inadequately addressed conditions that do not characteristically fall 
into a single organ category but can have a major impact on quality of life. Identification of 
these ‘frailty syndromes’ can help health care professionals manage and potentially delay 
their complications. These, often inter-related syndromes, include but are not limited to falls, 
delirium, weight loss and malnutrition, fluctuating disability, polypharmacy, social isolation, 
fragility fracture(s) and recurrent hospital admissions (Figure 3).
Figure 3. Consequences of living with frailty.
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3.2. Prevalence of frailty
Given poor outcomes relating to morbidity, mortality and disability, it is useful to understand 
the prevalence of frailty to inform the provision of appropriate health and social care inter-
ventions. Prevalence figures have been well documented in many OECD (Convention of the 
Organisation for Economic Cooperation and Development) countries such a USA, Canada, 
Netherlands and the UK but data on relative incidence in developing countries is sparse [49]. 
Prevalence estimates based on 21 cohorts of 61,500 community-dwelling older adults across 
mainly developed countries estimated frailty prevalence between 4 and 59% and varied 
according to the operational definitions, for example, the physical phenotype versus frailty 
index-based models. However, there was general agreement that frailty increases with age 
and is higher in women than in men. In populations aged 80–84, the pooled prevalence rate 
was reported to be 15.7% whilst in those over 85 the prevalence increased to 26% [49]. This 
figure may be substantially higher in institutionalised older people. In an analysis of the 
Study on health, Ageing and Retirement in Europe, SHARE (n = 18,566) and Study on global 
AGEing and adult health, SAGE (n = 161,542), two large international data sets of adults over 
50 years in which a frailty index was calculated, more women were classed as frail and frailty 
as a syndrome was distributed along the socioeconomic gradient amongst both higher and 
lower income countries such that individuals with less education and monetary income were 
more likely to be frail [48]. Recently, a study of 5450 older people aged 60 and over participat-
ing in the English Longitudinal Study of Ageing (ELSA) reported that the prevalence of frailty 
using the physical frailty phenotype rose from 6.5% in those aged 60–69 to 65% in those over 
the age of 90, with frail individuals reporting decreased physical function and difficulties in 
performing activities of daily living [50].
3.3. Interventions for individuals living with sarcopenia and frailty
A multi-dimensional approach to managing sarcopenia and indeed frailty involves promot-
ing physical activity, optimising nutrition/prevention of malnutrition, minimising polyphar-
macy and attending to and individual’s social and psychological aspects of health, that is, 
care support and home adaptations. Management goals for an older person with sarcopenia 
or frailty revolve around improving physical function and maintaining independence and 
well-being.
Exercise and nutritional interventions that impact positively on muscle mass and function 
play a significant role in the management of sarcopenia. For example, combination physical 
activity and nutritional interventions are associated with better function, strength and less 
inflammation in older sarcopenic people [61, 62]. In terms of physical activity, progressive 
resistance and aerobic exercise have been shown to be the most beneficial for the preven-
tion and ‘treatment’ of sarcopenia [23, 63–65]. Whilst progressive resistance exercise improves 
lean mass, strength and function [66], optimising exercise capacity through aerobic activity 
improves metabolic control, reduces oxidative stress, insulin sensitivity and can stimulate a 
hypertrophic response on muscle fibres. Despite being shown to be safe and effective in older 
people [63, 67, 68], implementing progressive exercise in clinical practice is not always readily 
achievable.
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Falls are serious and sometimes fatal complications of sarcopenia. In this regard, a multi-
component approach that addresses balance and gait, flexibility and endurance, lower limb 
strengthening exercises is required to manage fallers. Such approaches are associated with 
improved reaction time, gait, balance, strength coordination and physical and cognitive func-
tion [69, 70]. Group and home-based exercise programmes, which incorporate safety inter-
ventions, may reduce the rate and risk of falling [71]. Moreover, targeted home-based or 
group-based exercise interventions can also improve mobility and functional outcomes for 
older people with frailty [72, 73].
Intervening earlier in the life course before the onset of sarcopenia may have immense ben-
efits for later skeletal muscle health. For example, increased levels of leisure time physical 
activity in mid-life were associated with stronger grip strength in both men and women at 
age 60–64. This is consistent with optimising peak strength earlier in the life course, therefore 
reducing the impact of sarcopenia. Therefore, regular physical activity in adolescence and 
adulthood may prevent steep decline in muscle strength in early old age [74].
The synthesis of muscle fibres requires adequate protein substrates. Physiological 
changes in the gastrointestinal system occur with age and result in older people eat-
ing less, having early satiety, losing their sense of taste and having a blunted anabolic 
response to ingested proteins [75]. As such, older people may require more protein to 
counteract the inflammatory and catabolic effects of co-existent co morbidities and their 
exacerbations [76]. Protein supplements vary in their composition and evidence from 
trials at present is inconstant to develop evidence-based recommendations for protein 
supplementation in sarcopenia [77]. However, observational evidence suggests essen-
tial amino acids, that is, leucine, beta-hydroxy-beta-methylbutyrate (HMB), a bioactive 
metabolite of leucine, stimulates muscle protein synthesis more than non-essential amino 
acids and may be useful for maintain lean body mass and improving muscle function 
[78–82]. A recent consensus statement from the multinational PROT-AGE group recom-
mends protein intake in older people of at least 1.2–1.5 g of protein per body weight (kg) 
a day to maintain muscle homeostatsis [83]. Nutritional interventions in sarcopenia are 
covered in more detail elsewhere in this book.
3.4. Possible targets for pharmacological treatment
Observational studies indicate the potential beneficial effects of testosterone on muscle mass 
and function given the associated anabolic and satellite cell stimulatory activity. Randomised 
controlled trials of testosterone have not demonstrated benefits on muscle function because of 
adverse cardiovascular outcomes [34]. Studies of growth hormone (GH) supplementation have 
shown more harm than benefit in older patients; whilst GH therapy may increase muscle mass, 
it has not always increased muscle strength or functional performance. Moreover, unwanted 
side effects precludes GH as a treatment for sarcopenia. These include arthralgia, paraesthesia, 
fatigue, carpal tunnel syndrome and mortality in some observational human studies [84, 85].
There has been interest in selective androgen receptor modulators (SARMS) for sarcopenia 
treatment, which stems from the observed anabolic effect of testosterone. SARMS are andro-
gen receptor ligands that display selective activation of androgen signalling in target tissues, 
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for example, skeletal muscle. However, none are in clinical use and trials will be needed on 
the safety and efficacy of SARMS in improving physical function in older people with sarco-
penia [34, 86].
Myostatin, a member of the TGF-β superfamily, is a negative regulator of skeletal muscle 
growth and is upregulated in many muscle wasting disorders [87]. Based on these obser-
vations, myostatin and its receptor activin type IIb pose attractive targets for therapeutic 
intervention. Though there are currently no anti-myostatin drugs used in clinical practice, 
myostatin receptor antibodies are currently under review with the focus on older people with 
lower lean mass [34].
Angiotensin-converting enzyme inhibitor (ACEi), for example, perindopril, use was associ-
ated with improvement in 6-m walk tests in older persons with functional impairment but 
did not show increased benefit with additional exercise training. Whilst ACEi use may have 
beneficial effects on muscle function [88], a recent meta-analysis of four trials concluded that 
ACEi did not improve walk distance or age-related strength decline in older people therefore, 
further evidence from clinical trials are needed [89].
3.5. Comprehensive Geriatric Assessment (CGA)
Frailty is a dynamic process that predisposes an individual to a spiral of decline that leads 
to increasing frailty and risk of worsening disability, predisposition to falls, hospital as well 
as care home admission and death [51, 58]. Although current screening for frailty identifies 
individuals at risk, validated tools do not recommend intervention. It is imperative that when 
managing frailty, assessments should not only seek to determine and treat specific illnesses, 
but that they should endeavour to maintain and where possible, improve quality of life. It is 
clear that older person’s needs are more complex and that they often have co-existent func-
tional, psychological and social needs. This predisposes an individual to atypical clinical pre-
sentations that can often be misunderstood and which often require a different approach to 
care that diverts away from an organ specific diagnosis towards a holistic and integrated view 
of their problems.
Older people and their caregivers should purposefully be involved in making informed deci-
sions relating to health and social care needs as well as advanced care planning. A useful 
method for planning the care of those living with moderate to severe frailty through a pro-
cess of assessment, summation, conversation, planning, intervention, monitoring and review 
is Comprehensive Geriatric Assessment (CGA). CGA is a process, which is patient centred, 
responsive, adaptable and most effective when disseminated amongst key professionals 
working across the acute and community sectors. CGA is defined as a ‘multidimensional inter-
disciplinary diagnostic process focused on determining a frail older person’s medical, psychological and 
functional capability in order to develop a coordinated and integrated plan for treatment and long term 
follow up’ [90].
The purpose of CGA is to improve diagnostic accuracy, optimise treatment and out-
comes and crucially, allow effective integrated case management to ensure that the care 
plan is enacted and remains responsive to the patient’s needs over time. CGA requires the 
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systematic evaluation of physical, functional, medical, nutritional, cognitive and social 
components that influences an older person’s health that can also extend to financial, 
spiritual, psychological and palliative needs (Figure 4). How CGA is delivered is variable 
and very much depends on the care setting, for example, home, hospital, clinic or nursing 
home but, to be effective, often requires coordination of several inter-professional services 
that can include clinicians, community nursing, therapy, social services, pharmacy, nutri-
tion and dietetics, optometry and audiology. There are no set universal criteria to identify 
patients in need for a CGA however, patients who are ‘too well’ or are ‘too sick’ are less 
likely to derive benefit from the process. CGA becomes important for patients who are 
identified as living with frailty through the use of validated instruments or have one or 
more of the ‘frailty syndromes’ previously mentioned. There is evidence from multiple 
meta-analyses that CGA delivered to patients within the hospital setting as well as in the 
community is associated with better function and cognition, decrease in mortality, less 
likelihood of being institutionalised, less likelihood of patients experiencing deterioration 
in their health [90–93].
A critical component of CGA is a medication review and the STOPP/START approach 
to polypharmacy is a useful evidence-based tool [94]. The well-being components of 
the CGA may include the promotion of regular physical activity and exercise delivered 
through home-based plans [95] or external activity classes, social engagement through 
day centres and community networks, adaptations to the home environment to assist 
with falls prevention, caregiver support and nutritional optimisation. By undertaking a 
CGA with the person and those closest to them, if they wish, individuals are able to 
identify their own personal goals therefore reclaiming some of the lost independence 
they may have encountered as a result of living with frailty. Equally, the process will 
enable appropriate advanced care planning discussions for individuals with severe frailty 
in conjunction with palliative care support for those who may be entering the terminal 
phase of their life.
Figure 4. Core components of an inter-professional Comprehensive Geriatric Assessment. The process involves 
data gathering, multidisciplinary team discussions, development of the plan with the patient and their caregiver, 
implementation, monitoring and revision of the plan so that it remains responsive to the needs of the patient.




Sarcopenia and frailty are inter-related conditions that are common in older age and identify 
people who have an increased risk of a range of adverse outcomes. Sarcopenia has a complex 
aetiology involving neurohormonal, immunological and nutritional mechanisms. Frailty is 
a multisystem disorder, which commonly includes sarcopenia as a core component. Whilst 
there are clear physiological and pathophysiological explanations for the development and 
definition of frailty, there is need to understand that frailty as a term can be perceived as a 
state of dependency, subjugation or defeat; the appearance of being weak in later life. Not 
all older people are frail. These connotations and negative perceptions need to be challenged 
through education and training.
There is robust evidence to support the implementation of exercise and activity programmes 
for older people with sarcopenia and frailty, and that the adverse health trajectories of frailty 
may be modified through a range of interventions through the process of Comprehensive 
Geriatric Assessment. Better identification of sarcopenia and frailty in older age enables pro-
active targeting of interventions to improve outcomes and modify future health trajectories 
that benefit older people as well as their caregivers.
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